Can a cancer drug wake up immune cells to beat HIV-Related infections?
NCT ID NCT07579247
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called Sintilimab, which is normally used for cancer, to see if it can help people with HIV who have infections that won't go away with standard treatment. The drug works by 'waking up' exhausted immune cells. Fifty adults with HIV and a hard-to-treat infection will receive three doses of Sintilimab alongside their usual care. Researchers will check if the infection clears and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sintilimab (a drug that blocks PD-1 to revive tired immune cells)
What this could lead to
If it works, this could offer a new way to treat hard-to-clear infections in people with advanced HIV, potentially reducing deaths from these infections.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply broadly. The drug can cause immune-related side effects, and it's not yet proven to work for infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, 201508, China
Contact Phone: •••-•••-•••• Email: •••••@•••••